Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 287,956 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 287,956 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total transaction of $5,666,974.08. Following the sale, the director owned 11,663 shares in the company, valued at $229,527.84. This represents a 96.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Up 2.4%

Shares of NASDAQ:DYN opened at $19.67 on Thursday. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15. The company has a fifty day simple moving average of $17.58 and a 200 day simple moving average of $18.36. The firm has a market cap of $3.25 billion, a PE ratio of -5.56 and a beta of 1.29. Dyne Therapeutics, Inc. has a 12-month low of $8.06 and a 12-month high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its holdings in Dyne Therapeutics by 9.0% in the third quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock worth $42,570,000 after purchasing an additional 278,466 shares during the period. Aberdeen Group plc boosted its holdings in Dyne Therapeutics by 15.0% in the third quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock worth $7,043,000 after purchasing an additional 72,770 shares during the period. Vanguard Group Inc. boosted its holdings in Dyne Therapeutics by 27.6% in the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock worth $123,469,000 after purchasing an additional 2,109,257 shares during the period. Rafferty Asset Management LLC boosted its holdings in shares of Dyne Therapeutics by 93.4% during the third quarter. Rafferty Asset Management LLC now owns 213,211 shares of the company’s stock valued at $2,697,000 after acquiring an additional 102,963 shares during the period. Finally, Integral Health Asset Management LLC acquired a new position in shares of Dyne Therapeutics during the third quarter valued at $10,120,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on DYN shares. Morgan Stanley dropped their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. HC Wainwright dropped their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Chardan Capital restated a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research note on Monday, March 9th. JPMorgan Chase & Co. dropped their price target on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.14.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.